Short Communications


Articles


CYP4F Enzymes Are Responsible for the Elimination of Fingolimod (FTY720), a Novel Treatment of Relapsing Multiple Sclerosis. Yi Jin, Markus Zollinger, Hubert Borell, Alfred Zimmerman, and Christopher J. Patten.


Disposition and Metabolism of [14C]SB-649868, an Orexin 1 and 2 Receptor Antagonist, in Humans. Cecilia Renzulli, Mike Nash, Mark Wright, Steven Thomas, Stefano Zamuner, Mario Pellegratti, Paolo Bettica, and Gary Boyle.

Metabolism and Disposition of 14C-Labeled Pelaglinizole in Humans. Lifei Wang, Carey Munisick, Sean Chen, Samuel Bonacorsi, Peter T. Cheng, W. Griffith Humphreys, and Donglu Zhang.


Influence of Cremophor EL and Genetic Polymorphisms on the Pharmacokinetics of Paclitaxel and Its Metabolites Using a Mechanism-Based Model. Martin N. Fransson, Henrik Gren, Jan-Eric Litton, and Lena E. Friberg.

Tissue Distribution and Elimination of 14C-Apixaban in Rats. Lifei Wang, Kan He, Brad Maxwell, Scott...
J. Grossman, Larry M. Tremaine, W. Griffith Humphreys, and Donglu Zhang .......... 256


Tissue Distribution and Characterization of Drug-Related Material in Rats and Dogs after Repeated Oral Administration of Casopitant. Sabrina Pagliarusalem, Silvia Martinucci, Ellenia Bordini, Lidia Miraglia, Domenico Cufari, Luca Ferrari, and Mario Pellegrat .......... 283


Brain Tissue Binding of Drugs: Evaluation and Validation of Solid Supported Porcine Brain Membrane Vesicles (TRANSIL) as a Novel High-Throughput Method. Raffaele Longhi, Silvia Corbioli, Stefano Fontana, Federica Vinco, Simone Braggio, Lydia Helmdach, Jürgen Schiller, and Hinnerk Boriss .......... 312

Correlation between Bilirubin Glucuronidation and Estradiol-3-Gluronidation in the Presence of Model UDP-Glucuronosyltransferase 1A1 Substrates/Inhibitors. Jin Zhou, Timothy S. Tracy, and Rory P. Remmel .......... 322


Identification and Validation of Novel Human Pregnan X Receptor Activators among Prescribed Drugs via Ligand-Based Virtual Screening. Yongmei Pan, Linhao Li, Gregory Kim, Sean Ekins, Hongbing Wang, and Peter W. Swaan. .......... 337

Inactivation of Cytochrome P450 (P450) 3A4 but not P450 3A5 by OSI-930, a Thiophene-Containing Anticancer Drug. Hsia-lien Lin, Haoming Zhang, Christine Medower, Paul F. Hollenberg, and William W. Johnson .......... 345

ERRATUM

Correction to “Identification of Clinically Utilized Drugs that Activate Pregnan X Receptors” .......... 351

Supplemental material is available online at http://dmd.aspetjournals.org.

About the cover: Molecular modeling showing the binding of OSI-930 in the active sites of P450 3A4 (A) and P450 3A5 (B). See the article by Lin et al. on page 345 of this issue.